Loading...
OTC Markets
Totals
Securities
12,304
Dollar Vol
$1.2B
Share Vol
2.5B
Trades
135,209

OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.

POSC
Positron Corp.

Common Stock

1.57

0.00

0.00%

1.55 / 1.60 (1 x 1)

Real-Time Best Bid & Ask: 12:06pm 06/16/2025
Delayed (15 Min) Trade Data: 12:00am 06/13/2025

0.00

N/A

0

N/A

Real-Time Level 2 Quote
Bid
Ask
MPID
MPID
Bid Price
Bid Price
Size
Size
Time
Time
ETRF
24.90>year
CDEL
21.9203/16
MACM
18.95>year
NITE
18.95>year
CSTI
18.55>year
MPID
MPID
Ask Price
Ask Price
Size
Size
Time
Time
INTL
19.40>year
NITE
19.40>year
MACM
19.43>year
MAXM
20.11>year
CANT
22.05>year
Unlock Real-Time quotes For POSCFind Out More
Trade Data
Date
Date
Timestamp
Timestamp
Price
Price
$ Change
$ Change
Volume
Volume
06/13/202512:22:45
1.57
0.02100
06/13/202512:22:36
1.55
0.05100
06/13/202511:52:42
1.50
0.01100
06/13/202511:51:42
1.485
0.00500
06/13/202511:51:27
1.485
-0.01500
More Irregular/odd lot trades, which are not considered for the Open, High, Low or Closing prices, are not shown in trade data table.
Company Description
Positron Corporation is a medical technology company that co-develops, manufactures, and sells state-of-the-art PET and PET-CT molecular imaging systems and clinical services to nuclear medicine healthcare providers throughout North America. Positron specializes in the field of cardiac PET imaging, the gold standard in nuclear cardiac diagnostics. Positron's innovative PET technology, clinical services and practice solutions enable healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes through providing superior cost-effective medicine. Positron has the exclusive North American distribution rights for the NeuSight PET-CT 3D 64 Slice scanner and ownership of the NeuSight FDA 510(k). Positron has also jointly developed a new Affinity PET-CT 4D 64 Slice system which it will manufacture, sell, service as well as provide clinical services and full support over the lifetime of the system. Positron's expansion to PET-CT was key to the Company's future in multiple imaging disciplines, likely setting Positron on a path for exponential growth with the NeuSight and Affinity PET-CT systems. Positron's PET-CT systems enable the Company to meet the new demands of the nuclear cardiology community and gives Positron the tools to enter and thrive in the oncology segment of the nuclear imaging market with what the Company's believes is the best product at the best price with the ability to service all healthcare providers.
Videos
Pink Open Market Logo
Pink Current Information
The Company Profile data was verified by the issuer within the previous 6 months.
The company’s transfer agent has verified its outstanding shares directly to OTC Markets.
Daily Advancers
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.